Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy

Adoptive T cell therapy (ACT) with expanded tumor-infiltrating lymphocytes (TIL) can induce durable responses in cancer patients from multiple histologies, with response rates of up to 50%. Antibodies blocking the engagement of the inhibitory receptor programmed cell death protein 1 (PD-1) have been...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Christopher Aled Chamberlain, Eric Paul Bennett, Anders Handrup Kverneland, Inge Marie Svane, Marco Donia, Özcan Met
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2022-03-01
Serie:	Molecular Therapy: Oncolytics
Ämnen:	adoptive cell therapy TIL therapy tumor-infiltrating lymphocytes CRISPR-Cas9 PD-1 immunotherapy
Länkar:	http://www.sciencedirect.com/science/article/pii/S2372770522000080
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!